TXG10x Genomics, Inc.
10x Genomics, Inc. (TXG) sells single-cell and spatial biology platforms for research and clinical applications. The next catalyst is Sep 21, 2026 — $TXG stock is up 4% today. Here's what we see in our data.
- Public fact: Free cash flow (TTM) stands at $204.13M .
- Scouter has modeled bull and bear paths into the next catalyst.
- Past catalysts are scored in The Read.
The schedule
- Thu5Nov
This earnings report will test the company's ability to deliver on its guidance, particularly in the genomics and sequencing space, amid rising competition and macroeconomic uncertainty. The outcome will be critical for P&L, product mix, and cash flow visibility.
- Tue9Feb
This report will test the company's ability to sustain growth in its sequencing and spatial biology platforms, particularly as it faces increased competition and potential pricing pressures.
- Fri7May
This report will test the company's ability to maintain momentum in its genomics and spatial biology platforms, particularly as it navigates macroeconomic headwinds and competition.
- Fri6Aug
This report will test the company's ability to maintain momentum in its genomics and spatial biology platforms, particularly as it navigates macroeconomic headwinds and competition.
Past
- Fri7Aug
Actual outcome: Bull · $56.09 at outcome
10x Genomics delivered a strong Q2 2026 report, beating revenue estimates and expanding its gross margins while meeting EPS expectations. The stock rallied well past the $52 bull target as the company raised its full-year 2026 revenue outlook, signaling robust commercial execution and demand for its platforms.
10x Genomics delivered a strong Q2 2026 report, beating revenue estimates and expanding its gross margins while meeting EPS expectations. The stock rallied well past the $52 bull target as the company raised its full-year 2026 revenue outlook, signaling robust commercial execution and demand for its platforms.
- Mon1Jun
Actual outcome: Bull · $29.18 at outcome
10x Genomics exceeded the bull target, closing at $29.18 on the outcome date and continuing a massive rally in the following months. The stock's upward trajectory was fueled by the strategic acquisition of Proteintech Genomics, which expanded the company's high-plex proteomics tools and strengthened its multiomics capabilities. This deal drove strong investor confidence in the broader adoption and long-term growth of the company's platforms.
10x Genomics exceeded the bull target, closing at $29.18 on the outcome date and continuing a massive rally in the following months. The stock's upward trajectory was fueled by the strategic acquisition of Proteintech Genomics, which expanded the company's high-plex proteomics tools and strengthened its multiomics capabilities. This deal drove strong investor confidence in the broader adoption and long-term growth of the company's platforms.
- Fri8May
Actual outcome: Mixed · $21.20 at outcome
10x Genomics beat Q1 estimates on both the top and bottom lines, reporting a narrower-than-expected loss of $0.10 per share driven by consumables growth, margin expansion, and lower operating costs. During the earnings call, management also highlighted the launch of Atera, a new spatial biology instrument platform described as the most significant product introduction in the company's history. While the initial price reaction was muted, these strong fundamental results and the new product launch fueled growing investor confidence, ultimately driving the stock to surge well past the bull target in the weeks following the print.
10x Genomics beat Q1 estimates on both the top and bottom lines, reporting a narrower-than-expected loss of $0.10 per share driven by consumables growth, margin expansion, and lower operating costs. During the earnings call, management also highlighted the launch of Atera, a new spatial biology instrument platform described as the most significant product introduction in the company's history. While the initial price reaction was muted, these strong fundamental results and the new product launch fueled growing investor confidence, ultimately driving the stock to surge well past the bull target in the weeks following the print.
- Sun5Apr
Actual outcome: Bull · $23.58 at outcome
10x Genomics shares rallied toward the bull target following a pre-event upgrade to Outperform by William Blair and growing investor enthusiasm for the company's role in AI-driven biological data. This momentum, supported by increased institutional accumulation, reflected strong market validation of the Xenium platform's application in high-value translational workflows showcased at AACR.
10x Genomics shares rallied toward the bull target following a pre-event upgrade to Outperform by William Blair and growing investor enthusiasm for the company's role in AI-driven biological data. This momentum, supported by increased institutional accumulation, reflected strong market validation of the Xenium platform's application in high-value translational workflows showcased at AACR.
- Fri20Mar
Actual outcome: Bull · $25.35 at outcome
While no explicit update on the patent litigation was announced, 10x Genomics revealed major partnerships in its spatial profiling technologies, including the STELA atlas with Bioptimus and a collaboration with PerturbAI and NVIDIA. These strategic developments, alongside analyst optimism regarding the company's consumables-led transition and dominant market share, reinforced long-term growth prospects and drove the stock well past the $21.00 bull target by the run date.
While no explicit update on the patent litigation was announced, 10x Genomics revealed major partnerships in its spatial profiling technologies, including the STELA atlas with Bioptimus and a collaboration with PerturbAI and NVIDIA. These strategic developments, alongside analyst optimism regarding the company's consumables-led transition and dominant market share, reinforced long-term growth prospects and drove the stock well past the $21.00 bull target by the run date.
- Fri13Feb
Actual outcome: Mixed · $18.62 at outcome
TXG reported Q4 2025 EPS of -$0.13, exactly in line with consensus estimates. The lack of a significant earnings surprise or major shifts in 2026 guidance led to a muted initial reaction, with the stock rising just 2.8% by the outcome date. However, shares steadily gained momentum in the following months, eventually approaching the bull target.
TXG reported Q4 2025 EPS of -$0.13, exactly in line with consensus estimates. The lack of a significant earnings surprise or major shifts in 2026 guidance led to a muted initial reaction, with the stock rising just 2.8% by the outcome date. However, shares steadily gained momentum in the following months, eventually approaching the bull target.
